RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday. They presently have a $2.00 price target on the biopharmaceutical company’s stock.

Shares of RegeneRx Biopharmaceuticals (RGRX) traded up 1.064% during midday trading on Thursday, reaching $0.285. The company’s stock had a trading volume of 54,829 shares. RegeneRx Biopharmaceuticals has a one year low of $0.22 and a one year high of $0.40. The company has a market capitalization of $30.46 million and a P/E ratio of 25.909. The stock’s 50-day moving average is $0.28 and its 200-day moving average is $0.28.

TRADEMARK VIOLATION NOTICE: “RegeneRx Biopharmaceuticals’ (RGRX) Buy Rating Reaffirmed at HC Wainwright” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/regenerx-biopharmaceuticals-rgrx-buy-rating-reaffirmed-at-hc-wainwright.html.

RegeneRx Biopharmaceuticals Company Profile

RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.

Receive News & Ratings for RegeneRx Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.